Statin Applications in Liver Disease Management

Statins, originally developed to lower circulating cholesterol by inhibiting HMG-CoA reductase, have emerged as multifaceted agents in the management of chronic liver disorders. Beyond lipid reduction, they exert anti‐inflammatory, antioxidant and antifibrotic effects, modulating key pathways such as NF-κB signalling and transforming growth factor-β activity. Experimental models of steatohepatitis demonstrate that statins attenuate hepatic stellate cell activation, reduce extracellular matrix deposition and preserve endothelial nitric oxide synthase activity. In clinical practice, large observational cohorts and controlled trials have linked long-term statin use with slower progression of fibrosis and cirrhosis, lower portal pressure and reduced incidence of hepatocellular carcinoma. In non-alcoholic fatty liver disease (NAFLD), where dyslipidaemia and insulin resistance drive both hepatic injury and cardiovascular risk, statin therapy provides dual benefit by improving atherogenic profiles and mitigating liver inflammation. Similarly, in viral hepatitis settings, dose-dependent reductions in cancer risk have been noted. Safety data indicate a favourable tolerance profile in compensated disease, though monitoring of transaminases and muscular symptoms remains essential. Globally, as the burden of fatty liver and virus-induced liver injury rises, repurposing statins offers a pragmatic strategy to integrate cardiovascular and hepatic care, with ongoing trials poised to refine optimal agents, dosing regimens and patient selection.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Statin Applications in Liver Disease Management publication trend

The graph below shows the total number of articles in statin applications in liver disease management across all publications each year (not limited to Nature Index journals).

Technical terms

Statin: A lipid-lowering drug class that inhibits HMG-CoA reductase, reducing cholesterol synthesis in hepatocytes.

Pleiotropic effects: Non-lipid-related actions of statins, including anti-inflammatory, antioxidant and antifibrotic properties.

Non-alcoholic fatty liver disease (NAFLD): Accumulation of triglycerides in hepatocytes in the absence of significant alcohol intake, often linked to metabolic syndrome.

Hepatocellular carcinoma (HCC): A primary malignant tumour of the liver, frequently arising on a background of chronic inflammation and cirrhosis.

Portal hypertension: Elevation of blood pressure within the portal venous system, commonly due to cirrhotic distortion of hepatic vasculature.

Fibrosis: Excessive deposition of extracellular matrix components in the liver, driven by activated stellate cells and chronic injury.

References

1. Statins: Old drugs as new therapy for liver diseases?. Journal of Hepatology (2018).
2. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells. BMC Gastroenterology (2015).
3. Simvastatin Ameliorates Liver Fibrosis via Mediating Nitric Oxide Synthase in Rats with Non-Alcoholic Steatohepatitis-Related Liver Fibrosis. PLOS ONE (2013).
4. Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus Infection. Journal of Clinical Oncology (2012).
5. Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis. Cancers (2020).
6. Statin Use and the Risk of Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies. Cancers (2020).
7. Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease. Current Atherosclerosis Reports (2022).
8. Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma. Oncotarget (2016).